SAN DIEGO, July 18, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ: ILMN) previously announced on June 24, the company will present a Strategy Update on Tuesday, August 13, 2024 starting at 8:00am Pacific Time. The event will feature presentations by members of Illumina's executive team and conclude with a Q&A session.
Webcast Details
The webcast can be accessed through the Events & Presentations section of Illumina's Investor Relations website at investor.illumina.com. We recommend that participants pre-register for the event on our website or using the following link: Illumina 2024 Strategy Update Registration. A replay will be posted on Illumina's Investor Relations website after the event and will be available for at least 30 days following.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube
Investors:
Salli Schwartz
+1.858.291.6421
ir@illumina.com
Media:
Bonny Fowler
+1.740.641.5579
pr@illumina.com
View original content:
SOURCE Illumina, Inc.
正如 Illumina, Inc. (納斯達克代碼:ILMN) 公司先前於2024年6月24日所宣佈的,公司將於2024年8月13日星期二早上8:00太平洋時間開始舉行策略更新活動。該活動將由 Illumina 執行團隊的成員進行演講,並在問答環節結束。
網絡研討會細節
網絡直播可通過 Illumina 的投資者關係網站(investor.illumina.com)的 事件和演示文稿 部分進行訪問。我們建議參與者使用我們的網站或以下鏈接預先註冊,以便參加此活動:Illumina 2024 策略更新註冊。活動後,回放將發佈在Illumina的投資者關係網站上,並且將可供至少30天。
關於Illumina
Illumina通過解鎖基因組的力量來提高人類健康水平。我們專注於創新,在DNA測序和基於陣列的技術方面,已被確認爲全球領先者,在生命科學,腫瘤學,生殖健康,農業和其他新興領域爲客戶服務。我們的產品用於生命科學,腫瘤學,生殖健康,農業和其他新興應用領域。要了解更多信息,請訪問illumina.com,並在X(Twitter),Facebook,LinkedIn,Instagram,TikTok和YouTube上與我們聯繫。
投資者:
Salli Schwartz
+1.858.291.6421
ir@illumina.com
媒體:
Bonny Fowler
+1.740.641.5579
pr@illumina.com
查看原始內容:
來源: Illumina, Inc.